Clinical data have demonstrated the therapeutic effects of anti-TNF-α therapies against autoimmune diseases, including rheumatoid arthritis, juvenile rheumatoid arthritis, inflammatory bowel disease (IBD), ankylosing spondylitis, psoriasis, and psoriatic arthritis [39,40]. This evidence concerns the gene TNF and ankylosing spondylitis.